AI주식인사이트AI Stock Insight
C

보로노이

310210KOSDAQ자연과학 및 공학 연구개발업

47.8 / 100

Reference Date: 2026-07-24

Financial Score12.5 / 40
News Sentiment21.3 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Plunged 32.6% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Boronoai is a biotech company specializing in the development of targeted therapies for cancers such as lung and breast cancer, leveraging its in-house research facilities and AI platforms to conduct early clinical trials and pursue a global licensing-out (License-Out) business model. The company focuses on kinase inhibitors, leveraging its expertise and accelerated development timelines to build competitive pipelines.

Number of Employees

149people

Average Salary

81.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 43.644.0Point
PBR
—Industry Average 2.523.5Point
ROE
-50.18Industry Average -32.093.5Point

1.6x industry avg (good)

Debt Ratio
57.37Industry Average 7.310.0Point

7.8x industry avg (risky)

Trend 2023~20251.5 / 10 points
Revenue Growth Rate
1.5 / 3

Operating Profit Growth Rate
0.0 / 3

Avg ▼32.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -52.7% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (9%, downtrend)

Current 133,500Won52-week high 363,50052-week low 108,500
1-month return0.0Point

1m -32.61% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0
  • Neutral[기재정정]투자판단관련주요경영사항(임상시험계획변경승인신청) (VRN110755의 제 1/2상 임상시험)2026-07-08
  • Neutral기업설명회(IR)개최2026-07-06
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-03
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-03
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-03